Mouse Models

Mouse models are already essential for the measurement of a drug candidate activity in pathophysiology of diseases. To date, there is no alternative method to in-vivo models for studying an integrated response involving nervous, endocrine, blood (hematopoietic), immunological and tissue systems. 
All purpose models were approved by the French Ministry of Education and Research (APAFIS).

Asthma models

The mouse responds to allergen administrations by an allergic-type response of the airways characterized by an influx of  inflammatory cells (eosinophils) , and a hyper-reactivity of the airways mimicking the asthmatic symptoms and allows the study of therapeutic targets.
We developed several models, well characterized and adapt to study potency of drug candidate.

  • Acute models (OVA ou HDM) : design to study anti-inflammatory activity
  • Chronic models (OVA ou HDM) : design to highlight activities on remodeling and hyper-reactivity
  • Atopic march model (HDM) : design to investigate activity on biological phenomena leading to skin inflammation, propagated at the systemic level to allow the development of an increase in asthma

Lung fibrosis models

Nasal administration of bleomycin induce an inflammatory response follow by the development of a lung fibrosis. This model is  robust and able to identified novel therapies.

Lung inflammation models to LPS (bacterial wall lipopolysaccharides)

The mouse responds to intranasal administration of LPS by a rapid and robust neutrophilic inflammatory response of the airways that allows the study of therapeutic targets and drug candidates with anti-inflammatory activity.

Atopic Dermatitis models

Atopic dermatitis may be induced by topical administration of calcipotriol (MC903, a precursor of vitamin D) to the ears of mice. Repeated administration of MC903 leads to sensitization and recruitment of eosinophils and macrophages in the ear tissues and is accompanied by skin irritation (swelling, pruritus, redness and desquamation).

Models of heterotopic grafting of tumor cells (cancer)

This model involves grafting tumor cells to a different site from the original tumor. These grafts are carried out subcutaneously, on the animal's flank, for easy grasping of the animal without risk of injury or pain, and which allows simple and rapid monitoring of tumor growth by caliper measurement. This model has the advantage of being suitable for most tumor lines available, whether of human or animal origin.

Notes and references


Ovalbumin (OVA), House dust mite (HDM)


Lehot et al. Pharmaceutics 2023, 15(6), 1643;
Rady et al. Bioconjug Chem. 2022 09 15; 2022;33(10):1860-1866
Segaud et al. Nat Commun. 2022 Sep 1;13(1):4703.
Schall et al. Front Pharmac
ol. 2021 Oct 21;12:752194.
Daubeuf et al. Cells. 2021 Sep 18;10(9):2468
Daubeuf et al. Methods in Molecular Biology
, 2021, 2241:75-87
Hua et al. Proc Natl Acad Sci U S A. 2019 Jul 9;116(28):14191-14199
Daubeuf et al. Methods in Molecular Biology
, 2014 , 1178:283-9
Daubeuf et al. Current Protocols in Mouse Biology 2013, 3:31–37


Plateforme de Chimie Biologique Intégrative de Strasbourg (PCBIS - UAR3286)
74 route du Rhin
CS 60024